Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in fireside...
May 18, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra

SOUTH SAN FRANCISCO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company's Phase 1/2 study (MAA-202) of...
May 13, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside...
May 06, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021...
May 05, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the dosing of the first patient in the Crimson 1 Study, the Company's Phase 3...
April 19, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology

SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the publication of preclinical data from its study of CB 2679d-GT in...
April 12, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders

SOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S....
April 07, 2021 16:05 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will present a corporate...
March 04, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year...
February 18, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its executive management team will participate in a...